NEW YORK, Nov. 18 (GenomeWeb News) - Chemicon International, a division of Serologicals, said today that it has entered into an exclusive licensing agreement for Genome BioSciences' Positive-Positive Selection (PPS) gene-targeting technology.
Under the agreement, Chemicon will have the exclusive right to use the PPS technology for generating genetically modified cell lines and mice for its customers. Chemicon said it will also retain exclusive rights to grant third-party technology sublicenses to the PPS technology.
In addition, Rob Burgess, Genome BioSciences President, will join Chemicon as senior director of functional genomics while remaining a director of Genome BioSciences.
Financial terms of the licensing agreement were not disclosed.
Chemicon said that Genome BioSciences' technology is "the first in a series of platform technologies" it expects to license in support of a new functional genomics initiative at the company.